EMERYVILLE, Calif.–(BUSINESS WIRE)—- $OABI #OABI–OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an effici
